Introduced Version






SENATE BILL No. 132

_____


DIGEST OF INTRODUCED BILL



Citations Affected: IC 35-31.5-2-321.

Synopsis: Synthetic drugs. Removes mitragynine and 7-hydroxymitragynine from the definition of "synthetic drug".

Effective: July 1, 2013.





Kruse




    January 7, 2013, read first time and referred to Committee on Corrections & Criminal Law.







Introduced

First Regular Session 118th General Assembly (2013)


PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in this style type, and deletions will appear in this style type.
Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in this style type. Also, the word NEW will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.
Conflict reconciliation: Text in a statute in this style type or this style type reconciles conflicts between statutes enacted by the 2012 Regular Session of the General Assembly.

SENATE BILL No. 132



    A BILL FOR AN ACT to amend the Indiana Code concerning criminal law and procedure.

Be it enacted by the General Assembly of the State of Indiana:

SOURCE: IC 35-31.5-2-321; (13)IN0132.1.1. -->     SECTION 1. IC 35-31.5-2-321, AS ADDED BY P.L.114-2012, SECTION 67, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2013]: Sec. 321. "Synthetic drug" means:
        (1) a substance containing one (1) or more of the following chemical compounds, including an analog of the compound:
            (A) JWH-015 ((2-Methyl-1-propyl-1H-
            indol-3-yl)-1-naphthalenylmethanone).
            (B) JWH-018 (1-pentyl-3-(1-naphthoyl)indole).
            (C) JWH-019 (1-hexyl-3-(naphthalen-1-oyl)indole).
            (D) JWH-073
            (naphthalen-1-yl-(1-butylindol-3-yl)methanone).
            (E) JWH-081 (4-methoxynaphthalen- 1-yl- (1-pentylindol- 3-yl)methanone).
            (F) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
            (G) JWH-200 ((1-(2-morpholin-4-ylethyl)indol-3-yl)- naphthalen-1-yl-methanone).
            (H) JWH-250 (1-pentyl-3-(2-methoxyphenylacetyl)indole).
            (I) JWH-251 (1-pentyl-3-(2-methylphenylacetyl)indole).
            (J) JWH-398 (1-pentyl-3-(4-chloro-1-naphthoyl)indole).
            (K) HU-210 ((6aR,10aR)- 9-(Hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)-
            6a,7,10,10a-tetrahydrobenzo [c]chromen- 1-ol).
            (L) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo [c]chromen-1-ol).
            (M) HU-308 ([(1R,2R,5R)-2-[2,6-dimethoxy-4- (2-methyloctan- 2-yl)phenyl]-
            7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol).
            (N) HU-331 (3-hydroxy-2- [(1R,6R)-3-methyl-6- (1-methylethenyl)-2 -cyclohexen-1-yl]-5 -pentyl-2,5-cyclohexadiene-1,4-dione).
            (O) CP 55,940
            (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]- 5- (2-methyloctan-2-yl)phenol).
            (P) CP 47,497 (2-[(1R,3S)-3-hydroxycyclohexyl]- 5- (2-methyloctan-2-yl)phenol) and its homologues, or
            2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)
            phenol), where side chain n=5, and homologues where side chain n=4, 6, or 7.
            (Q) WIN 55212-2
            ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo [1,2,3-de)- 1,4- benzoxazin-
            6-yl]-1-napthalenylmethanone).
            (R) RCS-4 ((4-methoxyphenyl)
            (1-pentyl-1H-indol-3-yl)methanone).
            (S) RCS-8 (1-(1-(2-cyclohexylethyl)-1H-
            indol-3-yl)-2-(2-methoxyphenyl)ethanone).
            (T) 4-Methylmethcathinone. Other name: mephedrone.
            (U) 3,4-Methylenedioxymethcathinone. Other name: methylone.
            (V) Fluoromethcathinone.
            (W) 4-Methoxymethcathinone. Other name: methedrone.
            (X) 4-Ethylmethcathinone (4-EMC).
            (Y) Methylenedioxypyrovalerone. Other name: MDPV.
            (Z) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole.
            (AA) JWH-098, or
            1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole.
            (BB) JWH-164, or
            1-pentyl-3-(7-methoxy-1-naphthoyl)indole.
            (CC) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole.
            (DD) JWH-201, or
            1-pentyl-3-(4-methoxyphenylacetyl)indole.
            (EE) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole.
            (FF) AM-694, or
            1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole.
            (GG) CP 50,556-1, or
            [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpe ntan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1 -yl] acetate.
            (HH) Dimethylheptylpyran, or DMHP.
            (II) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP.
            (JJ) 6-APB [6-(2-aminopropyl)benzofuran].
            (LL) 7-hydroxymitragynine.
            (MM) (KK) .-PPP [.-pyrrolidinopropiophenone].
            (NN) (LL) .-PVP (desmethylpyrovalerone).
            (OO) (MM) AM-251.
            (PP) (NN) AM-1241.
            (QQ) (OO) AM-2201.
            (RR) (PP) AM-2233.
            (SS) (QQ) Buphedrone.
            (TT) (RR) Butylone.
            (UU) (SS) CP-47,497-C7.
            (VV) (TT) CP-47,497-C8.
            (WW) (UU) Desoxypipradol.
            (XX) (VV) Ethylone.
            (YY) (WW) Eutylone.
            (ZZ) (XX) Flephedrone.
            (AAA) (YY) JWH-011.
            (BBB) (ZZ) JWH-020.
            (CCC) (AAA) JWH-022.
            (DDD) (BBB) JWH-030.
            (EEE) (CCC) JWH-182.
            (FFF) (DDD) JWH-302.
            (GGG) (EEE) MDAI [5,6-methylenedioxy-2-aminoindane].
            (HHH) Mitragynine.
            (III) (FFF) Naphyrone.
            (JJJ) (GGG) Pentedrone.
            (LLL) (HHH) Pentylone.
            (MMM) (III) Methoxetamine
            [2-(3-methoxyphenyl)-2-(ethylamino)- cyclohexanone].
        (2) Any compound structurally derived from

3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
        (3) Any compound structurally derived from 3-(1-naphthoyl) pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
        (4) Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
        2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.
        (5) Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
        1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.
        (6) Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
        2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent.
        (7) Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.
        (8) Any compound, except bupropion or a compound listed under

a different schedule, structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified:
            (A) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
            (B) by substitution at the 3-position with an acyclic alkyl substituent;
            (C) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups; or
            (D) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
        (9) Any compound determined to be a synthetic drug by rule adopted under IC 25-26-13-4.1.